自家幹細胞と非幹細胞ベースの治療法の世界市場

自家幹細胞と非幹細胞ベースの治療法の世界市場は2030年までに126億米ドルに到達

2024年に54億米ドルと推定される自家幹細胞と非幹細胞ベースの治療法の世界市場は、2030年には126億米ドルに達し、分析期間2024-2030年のCAGRは15.0％で成長すると予測されます。本レポートで分析したセグメントの一つである自己幹細胞は、CAGR 16.7%を記録し、分析期間終了時には87億米ドルに達すると予測されます。自己幹細胞以外のセグメントの成長率は、分析期間中CAGR 11.5%と推定されます。

米国市場は15億米ドルと推定、中国はCAGR 20.2％で成長予測

米国の自家幹細胞と非幹細胞ベースの治療法市場は、2024年には15億米ドルになると推定されます。世界第2位の経済大国である中国は、2030年までに28億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは20.2%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ10.8％と13.5％と予測されています。欧州では、ドイツがCAGR 11.9%で成長すると予測されています。

世界の自家幹細胞と非幹細胞ベースの治療法市場- 主要動向と促進要因のまとめ

個別化医療はどのように自己細胞ベースの治療法の台頭を促しているのか？

自家幹細胞と非幹細胞ベースの治療法の出現は、個別化された患者固有の治療モデルを目指す世界の動きによって、再生医療の展望を急速に再構築しています。自己細胞療法は、患者自身の体から細胞を採取し、それを加工して、損傷した組織や臓器の治療や修復のために再導入するものです。これによって、同種移植で一般的な問題である免疫拒絶のリスクが排除され、生体適合性が向上します。幹細胞に基づく応用、特に間葉系幹細胞（MSC）、造血幹細胞（HSC）、あるいは人工多能性幹細胞（iPSC）を用いた応用は、変形性関節症、心筋梗塞、神経変性疾患、自己免疫疾患などの治療のために研究されています。非幹細胞側では、血小板豊富血漿（PRP）、線維芽細胞、軟骨細胞を用いた自家治療が、整形外科、皮膚科、美容医療で人気を集めています。細胞分離技術、凍結保存、3Dバイオプロセスの進歩により、自家療法はより効率的で臨床的に実行可能なものとなっています。これらの技術革新は、特にスポーツ傷害の回復や創傷治癒において、即日処置を可能にするポイント・オブ・ケア処理システムの利用拡大によってさらに後押しされています。さらに、規制当局が自己由来製品についてより明確な道筋を定め始めていることも、業界の信頼と研究投資を高めています。ヘルスケア部門が低侵襲で患者中心の介入を重視し続ける中、自家療法は、生物学的適合性と再生可能性を融合させたオーダーメイドのソリューションを提供し、個別化医療の未来の礎石となりつつあります。

市場拡大における臨床応用と疾病負担の役割は？

自家幹細胞と非幹細胞ベースの治療法の臨床応用は、慢性疾患や変性疾患の世界的負担の増大に直接対応して加速しています。変形性関節症、腱鞘炎、脊椎椎間板変性症などの筋骨格系疾患は需要を牽引する主要な疾患の一つであり、患者は非外科的治療や再生治療の選択肢を求めるようになっています。循環器内科では、心臓発作後に損傷した心筋を再生する自己幹細胞治療が評価されつつあり、既存の治療では根本的な原因に対処するよりも症状の改善が中心であったこの分野に新たな希望をもたらしている。神経学分野では、多発性硬化症、パーキンソン病、脊髄損傷などの疾患に対する自己幹細胞の利用が、初期段階の臨床試験で検討されています。これらの応用は、修復と機能回復を促すために患者自身の生物学的材料を使用することの魅力を強調しています。病院の外では、PRPや脂肪由来細胞などの幹細胞以外のアプローチが、特に自然で低侵襲な治療への需要が高まっているスポーツ医学や美容皮膚科などの外来診療に浸透しつつあります。その魅力は、薬理学的介入と比較して副作用が少なく、結果が長続きする自家療法の可能性にもあります。臨床試験活動は世界的に増加しており、学術機関、バイオテクノロジー企業、政府の研究助成金によって、より幅広い適応症におけるこれらの治療法の有効性と安全性の検証が目指されています。データが蓄積され、臨床医と患者の双方に認知度が高まるにつれて、自家療法の市場はニッチな用途から、より主流の臨床診療へと拡大しつつあります。

技術革新とインフラ開発は、スケーラブルな成長を支えることができるか？

自家幹細胞と非幹細胞ベースの治療法の将来的なスケーラビリティは、実現可能な技術の継続的な進歩と専門的なインフラの開発に大きく依存しています。自己細胞治療の主な技術的課題のひとつは、臨床的に適切な期間内に患者固有の細胞を採取、処理、再接種することの複雑さにあります。これに対処するため、企業はプロトコルを標準化し、人的ミスを減らすクローズドループ処理システムや自動細胞培養プラットフォームに投資しています。バイオリアクターの設計、マイクロ流体工学、細胞拡大培地における革新は、治療効力を維持しながら高品質の細胞を大規模に培養することを可能にしています。これと並行して、凍結保存技術も改良され、反復治療や段階的治療に不可欠な自己細胞の長期生存性が確保されつつあります。もう一つの成長分野は、個別化治療における品質保証とトレーサビリティに不可欠な、患者追跡、細胞調達文書化、規制遵守のためのデジタルツールの開発です。病院システムや専門クリニックは、専用のクリーンルーム施設や医薬品製造管理及び品質管理基準（GMP）ラボを建設し、院内処理に対応しています。ロジスティクスも、コールドチェーンの革新やバイオメディカル宅配サービスとの提携を通じて最適化されています。このような技術的・インフラ的な強化が相まって、かつては労働集約的でニッチな治療法であったものが、再現可能でスケーラブルな治療法へと変貌を遂げつつあります。業務効率を改善しコストを削減することで、これらの進歩は、より広範な市場への浸透と長期的な商業的持続可能性の基礎を築きつつあります。

今日の世界市場展望を形成する主な成長促進要因は何か？

自家幹細胞と非幹細胞ベースの治療法市場の成長は、技術、臨床需要、規制の進化、消費者の嗜好に結びついた、いくつかの異なる、しかし相互に関連した力によって牽引されています。重要な原動力は、加齢に伴う変性疾患や慢性疾患の世界の増加であり、患者や医師が緩和ケアではなく機能回復を提供する再生療法を求めるようになっています。細胞加工、凍結保存、ポイント・オブ・ケア・デバイスの技術的進歩により、特に外来患者や外来環境において、これらの治療法はより利用しやすく、臨床的に実現可能なものとなっています。規制の枠組みは、自己由来製品特有の課題に徐々に適応しつつあり、多くの国で、早期に有効性が実証された治療法に対して、迅速承認や条件付き承認のパスウェイが導入されています。一方、個別化医療への傾向の高まりは、特に美容、整形外科、スポーツ医学への応用において、患者自身の生物学的材料を使用する治療への関心を高めています。消費者の健康意識の影響も強く、全人的な健康戦略の一環として、自己由来の選択肢を積極的に検討する患者が増加しています。研究機関側では、公的・私的研究資金が拡大し、市場の信頼性に不可欠な大規模臨床試験や検証研究を支援しています。バイオテクノロジー企業、研究センター、ヘルスケアプロバイダー間のパートナーシップは、イノベーションを促進すると同時に、多様な臨床環境における自己血治療の実用的な展開を可能にしています。最後に、GMPラボや移動式処理装置といった専門的なインフラが利用可能になりつつあることが、物流の障壁を減らし、クリニックがこれらの治療を安全かつ効果的に提供することを容易にしています。これらの成長要因が相まって、長期的な可能性を秘めたダイナミックで有望な市場環境が形成されつつあります。

セグメント

種類（自己幹細胞、自己非幹細胞）、用途（がん用途、神経変性疾患用途、心血管系疾患用途、整形外科疾患用途、その他用途）、エンドユーザー（病院エンドユーザー、外来手術センターエンドユーザー、調査施設エンドユーザー）

調査対象企業の例

• Aastrom Biosciences（now Vericel Corporation）
• Anterogen Co., Ltd.
• Athersys, Inc.
• BioCardia, Inc.
• BrainStorm Cell Therapeutics
• Caladrius Biosciences, Inc.
• Cellular Biomedicine Group
• Cynata Therapeutics
• Gamida Cell
• Holostem Terapie Avanzate
• Hope Biosciences
• Medipost Co., Ltd.
• Mesoblast Limited
• NantKwest（now part of ImmunityBio）
• Neuroplast BV
• Nuo Therapeutics, Inc.
• Orgenesis Inc.
• Regenexx
• TiGenix（now part of Takeda）
• Vericel Corporation

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market to Reach US$12.6 Billion by 2030

The global market for Autologous Stem Cell and Non-Stem Cell Based Therapies estimated at US$5.4 Billion in the year 2024, is expected to reach US$12.6 Billion by 2030, growing at a CAGR of 15.0% over the analysis period 2024-2030. Autologous Stem Cells, one of the segments analyzed in the report, is expected to record a 16.7% CAGR and reach US$8.7 Billion by the end of the analysis period. Growth in the Autologous Non-Stem Cells segment is estimated at 11.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.5 Billion While China is Forecast to Grow at 20.2% CAGR

The Autologous Stem Cell and Non-Stem Cell Based Therapies market in the U.S. is estimated at US$1.5 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.8 Billion by the year 2030 trailing a CAGR of 20.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 10.8% and 13.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 11.9% CAGR.

Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market - Key Trends & Drivers Summarized

How Is Personalized Medicine Driving the Rise of Autologous Cell-Based Therapies?

The emergence of autologous stem cell and non-stem cell based therapies is rapidly reshaping the landscape of regenerative medicine, driven by the global movement toward personalized and patient-specific treatment models. Autologous therapies involve harvesting cells from a patient’s own body, processing them, and reintroducing them to treat or repair damaged tissues and organs. This eliminates the risk of immune rejection, a common issue with allogeneic transplants, and enhances biocompatibility. Stem cell-based applications, particularly those using mesenchymal stem cells (MSCs), hematopoietic stem cells (HSCs), or induced pluripotent stem cells (iPSCs), are being explored for treating conditions such as osteoarthritis, myocardial infarction, neurodegenerative diseases, and autoimmune disorders. On the non-stem cell side, autologous treatments using platelet-rich plasma (PRP), fibroblasts, and chondrocytes are gaining traction in orthopedics, dermatology, and aesthetic medicine. Advancements in cell isolation techniques, cryopreservation, and 3D bioprocessing are making autologous therapies more efficient and clinically viable. These innovations are further supported by the growing use of point-of-care processing systems that enable same-day procedures, particularly in sports injury recovery and wound healing. Moreover, regulatory bodies are beginning to define clearer pathways for autologous products, which has increased both industry confidence and research investment. As the healthcare sector continues to emphasize minimally invasive, patient-centric interventions, autologous therapies are becoming a cornerstone of the future of individualized medicine, offering tailored solutions that blend biological compatibility with regenerative potential.

What Role Do Clinical Applications and Disease Burden Play in Market Expansion?

The clinical adoption of autologous stem cell and non-stem cell based therapies is accelerating in direct response to the rising global burden of chronic and degenerative diseases. Musculoskeletal conditions such as osteoarthritis, tendonitis, and spinal disc degeneration are among the leading drivers of demand, with patients increasingly seeking non-surgical and regenerative treatment alternatives. In cardiology, autologous stem cell therapies are being evaluated for their ability to regenerate damaged myocardium following heart attacks, offering new hope in a field where existing treatments primarily manage symptoms rather than address root causes. In neurology, early-phase trials are investigating the use of autologous cells for conditions like multiple sclerosis, Parkinson’s disease, and spinal cord injuries. These applications highlight the appeal of using a patient’s own biological material to stimulate repair and functional recovery. Outside of the hospital setting, non-stem cell approaches such as PRP and adipose-derived cells are making inroads into outpatient clinics, particularly in sports medicine and cosmetic dermatology, where demand for natural and minimally invasive therapies is growing. The appeal also lies in the potential for autologous therapies to offer longer-lasting results with fewer side effects compared to pharmacological interventions. Clinical trial activity is increasing worldwide, supported by academic institutions, biotech companies, and government research grants aiming to validate the efficacy and safety of these treatments across a broader range of indications. As data accumulates and awareness grows among both clinicians and patients, the market for autologous therapies is expanding from niche applications to more mainstream clinical practice.

Can Technological Innovation and Infrastructure Development Support Scalable Growth?

The future scalability of autologous stem cell and non-stem cell based therapies depends heavily on the continued advancement of enabling technologies and the development of specialized infrastructure. One of the main technical challenges of autologous treatments lies in the complexity of harvesting, processing, and reinfusing patient-specific cells within clinically relevant timeframes. To address this, companies are investing in closed-loop processing systems and automated cell culture platforms that standardize protocols and reduce human error. Innovations in bioreactor design, microfluidics, and cell expansion media are making it possible to culture high-quality cells at scale while maintaining therapeutic potency. In parallel, cryopreservation technologies are being refined to ensure the long-term viability of autologous cells, which is essential for repeated or staged treatments. Another area of growth is the development of digital tools for patient tracking, cell sourcing documentation, and regulatory compliance, which are crucial for quality assurance and traceability in personalized therapies. Hospital systems and specialized clinics are building dedicated cleanroom facilities and Good Manufacturing Practice (GMP) labs to accommodate in-house processing, while mobile processing units are emerging as a solution for remote or underserved areas. Logistics is also being optimized through cold chain innovations and partnerships with biomedical courier services. Collectively, these technological and infrastructural enhancements are transforming what was once a labor-intensive, niche procedure into a reproducible and scalable treatment option. By improving operational efficiency and reducing costs, these advancements are laying the foundation for broader market penetration and long-term commercial sustainability.

What Are the Key Growth Drivers Shaping the Global Market Outlook Today?

The growth in the autologous stem cell and non-stem cell based therapies market is driven by several distinct yet interconnected forces tied to technology, clinical demand, regulatory evolution, and consumer preferences. A significant driver is the global rise in age-related degenerative diseases and chronic conditions, prompting patients and physicians to seek regenerative therapies that offer functional recovery instead of palliative care. Technological advancements in cell processing, cryopreservation, and point-of-care devices have made these therapies more accessible and clinically feasible, especially in outpatient and ambulatory settings. Regulatory frameworks are gradually adapting to the unique challenges of autologous products, with many countries introducing fast-track or conditional approval pathways for therapies that demonstrate early efficacy. Meanwhile, the growing trend toward personalized medicine is fueling patient interest in treatments that use their own biological material, particularly in aesthetic, orthopedic, and sports medicine applications. The influence of consumer health awareness is also strong, with more patients willing to explore autologous options as part of holistic wellness strategies. On the institutional side, public and private research funding is expanding, supporting large-scale clinical trials and validation studies that are critical for market credibility. Partnerships between biotech firms, research centers, and healthcare providers are facilitating innovation while enabling the practical deployment of autologous therapies across diverse clinical environments. Finally, the increasing availability of specialized infrastructure such as GMP labs and mobile processing units is helping to reduce logistical barriers, making it easier for clinics to offer these treatments safely and effectively. Together, these growth drivers are shaping a dynamic and promising market landscape with strong long-term potential.

SCOPE OF STUDY:

The report analyzes the Autologous Stem Cell and Non-Stem Cell Based Therapies market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Autologous Stem Cells, Autologous Non-Stem Cells); Application (Cancer Application, Neurodegenerative Disorders Application, Cardiovascular Disease Application, Orthopedic Diseases Application, Other Applications); End-User (Hospitals End-User, Ambulatory Surgery Centers End-User, Research Facilities End-User)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 32 Featured) -

• Aastrom Biosciences (now Vericel Corporation)
• Anterogen Co., Ltd.
• Athersys, Inc.
• BioCardia, Inc.
• BrainStorm Cell Therapeutics
• Caladrius Biosciences, Inc.
• Cellular Biomedicine Group
• Cynata Therapeutics
• Gamida Cell
• Holostem Terapie Avanzate
• Hope Biosciences
• Medipost Co., Ltd.
• Mesoblast Limited
• NantKwest (now part of ImmunityBio)
• Neuroplast BV
• Nuo Therapeutics, Inc.
• Orgenesis Inc.
• Regenexx
• TiGenix (now part of Takeda)
• Vericel Corporation

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Autologous Stem Cell and Non-Stem Cell Based Therapies - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Regenerative Potential of Autologous Stem Cells Strengthens the Business Case for Targeted Tissue Repair
  • Personalized Medicine Momentum Spurs Growth in Autologous Cell-Based Therapies
  • Growing Pipeline of Clinical Trials Expands the Addressable Market for Autologous Therapies
  • Minimized Risk of Immune Rejection Drives Adoption of Patient-Derived Cell Solutions
  • Orthopedic and Musculoskeletal Disorders Propel Demand for Non-Stem Cell Autologous Treatments
  • Aging Population and Degenerative Disease Burden Generate Long-Term Demand for Regenerative Interventions
  • Improved Cell Harvesting and Processing Technologies Accelerate Therapy Scalability
  • Shift Toward Outpatient and Point-of-Care Procedures Drives Interest in Minimally Invasive Autologous Solutions
  • Regulatory Pathways for Autologous Therapies Create Opportunities and Challenges in Market Entry
  • Expanded Use in Cosmetic and Aesthetic Applications Opens New Revenue Channels for Non-Stem Cell Therapies
  • Integration of 3D Bioprinting and Cell Scaffolding Enhances the Therapeutic Value of Autologous Approaches
  • Rising Interest in Immune Modulation Throws the Spotlight on Autologous Therapies for Autoimmune Conditions
  • Growing Demand for Alternatives to Allogeneic Products Sustains Market Preference for Autologous Options
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Autologous Stem Cell and Non-Stem Cell Based Therapies Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Autologous Stem Cell and Non-Stem Cell Based Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Autologous Stem Cell and Non-Stem Cell Based Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 4: World 16-Year Perspective for Autologous Stem Cell and Non-Stem Cell Based Therapies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Autologous Stem Cells by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Autologous Stem Cells by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 7: World 16-Year Perspective for Autologous Stem Cells by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Autologous Non-Stem Cells by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Autologous Non-Stem Cells by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 10: World 16-Year Perspective for Autologous Non-Stem Cells by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Research Facilities End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Research Facilities End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 13: World 16-Year Perspective for Research Facilities End-User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Hospitals End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Hospitals End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 16: World 16-Year Perspective for Hospitals End-User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Ambulatory Surgery Centers End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Ambulatory Surgery Centers End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 19: World 16-Year Perspective for Ambulatory Surgery Centers End-User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 22: World 16-Year Perspective for Cancer Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Neurodegenerative Disorders Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Neurodegenerative Disorders Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 25: World 16-Year Perspective for Neurodegenerative Disorders Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Cardiovascular Disease Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Cardiovascular Disease Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 28: World 16-Year Perspective for Cardiovascular Disease Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Orthopedic Diseases Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Orthopedic Diseases Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 31: World 16-Year Perspective for Orthopedic Diseases Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 34: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Autologous Stem Cell and Non-Stem Cell Based Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 35: USA Recent Past, Current & Future Analysis for Autologous Stem Cell and Non-Stem Cell Based Therapies by Type - Autologous Stem Cells and Autologous Non-Stem Cells - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 36: USA Historic Review for Autologous Stem Cell and Non-Stem Cell Based Therapies by Type - Autologous Stem Cells and Autologous Non-Stem Cells Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 37: USA 16-Year Perspective for Autologous Stem Cell and Non-Stem Cell Based Therapies by Type - Percentage Breakdown of Value Sales for Autologous Stem Cells and Autologous Non-Stem Cells for the Years 2014, 2025 & 2030
  • TABLE 38: USA Recent Past, Current & Future Analysis for Autologous Stem Cell and Non-Stem Cell Based Therapies by End-user - Research Facilities End-User, Hospitals End-User and Ambulatory Surgery Centers End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 39: USA Historic Review for Autologous Stem Cell and Non-Stem Cell Based Therapies by End-user - Research Facilities End-User, Hospitals End-User and Ambulatory Surgery Centers End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 40: USA 16-Year Perspective for Autologous Stem Cell and Non-Stem Cell Based Therapies by End-user - Percentage Breakdown of Value Sales for Research Facilities End-User, Hospitals End-User and Ambulatory Surgery Centers End-User for the Years 2014, 2025 & 2030
  • TABLE 41: USA Recent Past, Current & Future Analysis for Autologous Stem Cell and Non-Stem Cell Based Therapies by Application - Cancer Application, Neurodegenerative Disorders Application, Cardiovascular Disease Application, Orthopedic Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 42: USA Historic Review for Autologous Stem Cell and Non-Stem Cell Based Therapies by Application - Cancer Application, Neurodegenerative Disorders Application, Cardiovascular Disease Application, Orthopedic Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 43: USA 16-Year Perspective for Autologous Stem Cell and Non-Stem Cell Based Therapies by Application - Percentage Breakdown of Value Sales for Cancer Application, Neurodegenerative Disorders Application, Cardiovascular Disease Application, Orthopedic Diseases Application and Other Applications for the Years 2014, 2025 & 2030
• CANADA
  • TABLE 44: Canada Recent Past, Current & Future Analysis for Autologous Stem Cell and Non-Stem Cell Based Therapies by Type - Autologous Stem Cells and Autologous Non-Stem Cells - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: Canada Historic Review for Autologous Stem Cell and Non-Stem Cell Based Therapies by Type - Autologous Stem Cells and Autologous Non-Stem Cells Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 46: Canada 16-Year Perspective for Autologous Stem Cell and Non-Stem Cell Based Therapies by Type - Percentage Breakdown of Value Sales for Autologous Stem Cells and Autologous Non-Stem Cells for the Years 2014, 2025 & 2030
  • TABLE 47: Canada Recent Past, Current & Future Analysis for Autologous Stem Cell and Non-Stem Cell Based Therapies by End-user - Research Facilities End-User, Hospitals End-User and Ambulatory Surgery Centers End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Canada Historic Review for Autologous Stem Cell and Non-Stem Cell Based Therapies by End-user - Research Facilities End-User, Hospitals End-User and Ambulatory Surgery Centers End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 49: Canada 16-Year Perspective for Autologous Stem Cell and Non-Stem Cell Based Therapies by End-user - Percentage Breakdown of Value Sales for Research Facilities End-User, Hospitals End-User and Ambulatory Surgery Centers End-User for the Years 2014, 2025 & 2030
  • TABLE 50: Canada Recent Past, Current & Future Analysis for Autologous Stem Cell and Non-Stem Cell Based Therapies by Application - Cancer Application, Neurodegenerative Disorders Application, Cardiovascular Disease Application, Orthopedic Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Canada Historic Review for Autologous Stem Cell and Non-Stem Cell Based Therapies by Application - Cancer Application, Neurodegenerative Disorders Application, Cardiovascular Disease Application, Orthopedic Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 52: Canada 16-Year Perspective for Autologous Stem Cell and Non-Stem Cell Based Therapies by Application - Percentage Breakdown of Value Sales for Cancer Application, Neurodegenerative Disorders Application, Cardiovascular Disease Application, Orthopedic Diseases Application and Other Applications for the Years 2014, 2025 & 2030
• JAPAN
  • Autologous Stem Cell and Non-Stem Cell Based Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 53: Japan Recent Past, Current & Future Analysis for Autologous Stem Cell and Non-Stem Cell Based Therapies by Type - Autologous Stem Cells and Autologous Non-Stem Cells - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Japan Historic Review for Autologous Stem Cell and Non-Stem Cell Based Therapies by Type - Autologous Stem Cells and Autologous Non-Stem Cells Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 55: Japan 16-Year Perspective for Autologous Stem Cell and Non-Stem Cell Based Therapies by Type - Percentage Breakdown of Value Sales for Autologous Stem Cells and Autologous Non-Stem Cells for the Years 2014, 2025 & 2030
  • TABLE 56: Japan Recent Past, Current & Future Analysis for Autologous Stem Cell and Non-Stem Cell Based Therapies by End-user - Research Facilities End-User, Hospitals End-User and Ambulatory Surgery Centers End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Japan Historic Review for Autologous Stem Cell and Non-Stem Cell Based Therapies by End-user - Research Facilities End-User, Hospitals End-User and Ambulatory Surgery Centers End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 58: Japan 16-Year Perspective for Autologous Stem Cell and Non-Stem Cell Based Therapies by End-user - Percentage Breakdown of Value Sales for Research Facilities End-User, Hospitals End-User and Ambulatory Surgery Centers End-User for the Years 2014, 2025 & 2030
  • TABLE 59: Japan Recent Past, Current & Future Analysis for Autologous Stem Cell and Non-Stem Cell Based Therapies by Application - Cancer Application, Neurodegenerative Disorders Application, Cardiovascular Disease Application, Orthopedic Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Japan Historic Review for Autologous Stem Cell and Non-Stem Cell Based Therapies by Application - Cancer Application, Neurodegenerative Disorders Application, Cardiovascular Disease Application, Orthopedic Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 61: Japan 16-Year Perspective for Autologous Stem Cell and Non-Stem Cell Based Therapies by Application - Percentage Breakdown of Value Sales for Cancer Application, Neurodegenerative Disorders Application, Cardiovascular Disease Application, Orthopedic Diseases Application and Other Applications for the Years 2014, 2025 & 2030
• CHINA
  • Autologous Stem Cell and Non-Stem Cell Based Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 62: China Recent Past, Current & Future Analysis for Autologous Stem Cell and Non-Stem Cell Based Therapies by Type - Autologous Stem Cells and Autologous Non-Stem Cells - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: China Historic Review for Autologous Stem Cell and Non-Stem Cell Based Therapies by Type - Autologous Stem Cells and Autologous Non-Stem Cells Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 64: China 16-Year Perspective for Autologous Stem Cell and Non-Stem Cell Based Therapies by Type - Percentage Breakdown of Value Sales for Autologous Stem Cells and Autologous Non-Stem Cells for the Years 2014, 2025 & 2030
  • TABLE 65: China Recent Past, Current & Future Analysis for Autologous Stem Cell and Non-Stem Cell Based Therapies by End-user - Research Facilities End-User, Hospitals End-User and Ambulatory Surgery Centers End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: China Historic Review for Autologous Stem Cell and Non-Stem Cell Based Therapies by End-user - Research Facilities End-User, Hospitals End-User and Ambulatory Surgery Centers End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 67: China 16-Year Perspective for Autologous Stem Cell and Non-Stem Cell Based Therapies by End-user - Percentage Breakdown of Value Sales for Research Facilities End-User, Hospitals End-User and Ambulatory Surgery Centers End-User for the Years 2014, 2025 & 2030
  • TABLE 68: China Recent Past, Current & Future Analysis for Autologous Stem Cell and Non-Stem Cell Based Therapies by Application - Cancer Application, Neurodegenerative Disorders Application, Cardiovascular Disease Application, Orthopedic Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: China Historic Review for Autologous Stem Cell and Non-Stem Cell Based Therapies by Application - Cancer Application, Neurodegenerative Disorders Application, Cardiovascular Disease Application, Orthopedic Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 70: China 16-Year Perspective for Autologous Stem Cell and Non-Stem Cell Based Therapies by Application - Percentage Breakdown of Value Sales for Cancer Application, Neurodegenerative Disorders Application, Cardiovascular Disease Application, Orthopedic Diseases Application and Other Applications for the Years 2014, 2025 & 2030
• EUROPE
  • Autologous Stem Cell and Non-Stem Cell Based Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 71: Europe Recent Past, Current & Future Analysis for Autologous Stem Cell and Non-Stem Cell Based Therapies by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 72: Europe Historic Review for Autologous Stem Cell and Non-Stem Cell Based Therapies by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 73: Europe 16-Year Perspective for Autologous Stem Cell and Non-Stem Cell Based Therapies by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
  • TABLE 74: Europe Recent Past, Current & Future Analysis for Autologous Stem Cell and Non-Stem Cell Based Therapies by Type - Autologous Stem Cells and Autologous Non-Stem Cells - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Europe Historic Review for Autologous Stem Cell and Non-Stem Cell Based Therapies by Type - Autologous Stem Cells and Autologous Non-Stem Cells Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 76: Europe 16-Year Perspective for Autologous Stem Cell and Non-Stem Cell Based Therapies by Type - Percentage Breakdown of Value Sales for Autologous Stem Cells and Autologous Non-Stem Cells for the Years 2014, 2025 & 2030
  • TABLE 77: Europe Recent Past, Current & Future Analysis for Autologous Stem Cell and Non-Stem Cell Based Therapies by End-user - Research Facilities End-User, Hospitals End-User and Ambulatory Surgery Centers End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Europe Historic Review for Autologous Stem Cell and Non-Stem Cell Based Therapies by End-user - Research Facilities End-User, Hospitals End-User and Ambulatory Surgery Centers End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 79: Europe 16-Year Perspective for Autologous Stem Cell and Non-Stem Cell Based Therapies by End-user - Percentage Breakdown of Value Sales for Research Facilities End-User, Hospitals End-User and Ambulatory Surgery Centers End-User for the Years 2014, 2025 & 2030
  • TABLE 80: Europe Recent Past, Current & Future Analysis for Autologous Stem Cell and Non-Stem Cell Based Therapies by Application - Cancer Application, Neurodegenerative Disorders Application, Cardiovascular Disease Application, Orthopedic Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Europe Historic Review for Autologous Stem Cell and Non-Stem Cell Based Therapies by Application - Cancer Application, Neurodegenerative Disorders Application, Cardiovascular Disease Application, Orthopedic Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 82: Europe 16-Year Perspective for Autologous Stem Cell and Non-Stem Cell Based Therapies by Application - Percentage Breakdown of Value Sales for Cancer Application, Neurodegenerative Disorders Application, Cardiovascular Disease Application, Orthopedic Diseases Application and Other Applications for the Years 2014, 2025 & 2030
• FRANCE
  • Autologous Stem Cell and Non-Stem Cell Based Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 83: France Recent Past, Current & Future Analysis for Autologous Stem Cell and Non-Stem Cell Based Therapies by Type - Autologous Stem Cells and Autologous Non-Stem Cells - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: France Historic Review for Autologous Stem Cell and Non-Stem Cell Based Therapies by Type - Autologous Stem Cells and Autologous Non-Stem Cells Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 85: France 16-Year Perspective for Autologous Stem Cell and Non-Stem Cell Based Therapies by Type - Percentage Breakdown of Value Sales for Autologous Stem Cells and Autologous Non-Stem Cells for the Years 2014, 2025 & 2030
  • TABLE 86: France Recent Past, Current & Future Analysis for Autologous Stem Cell and Non-Stem Cell Based Therapies by End-user - Research Facilities End-User, Hospitals End-User and Ambulatory Surgery Centers End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: France Historic Review for Autologous Stem Cell and Non-Stem Cell Based Therapies by End-user - Research Facilities End-User, Hospitals End-User and Ambulatory Surgery Centers End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 88: France 16-Year Perspective for Autologous Stem Cell and Non-Stem Cell Based Therapies by End-user - Percentage Breakdown of Value Sales for Research Facilities End-User, Hospitals End-User and Ambulatory Surgery Centers End-User for the Years 2014, 2025 & 2030
  • TABLE 89: France Recent Past, Current & Future Analysis for Autologous Stem Cell and Non-Stem Cell Based Therapies by Application - Cancer Application, Neurodegenerative Disorders Application, Cardiovascular Disease Application, Orthopedic Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: France Historic Review for Autologous Stem Cell and Non-Stem Cell Based Therapies by Application - Cancer Application, Neurodegenerative Disorders Application, Cardiovascular Disease Application, Orthopedic Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 91: France 16-Year Perspective for Autologous Stem Cell and Non-Stem Cell Based Therapies by Application - Percentage Breakdown of Value Sales for Cancer Application, Neurodegenerative Disorders Application, Cardiovascular Disease Application, Orthopedic Diseases Application and Other Applications for the Years 2014, 2025 & 2030
• GERMANY
  • Autologous Stem Cell and Non-Stem Cell Based Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 92: Germany Recent Past, Current & Future Analysis for Autologous Stem Cell and Non-Stem Cell Based Therapies by Type - Autologous Stem Cells and Autologous Non-Stem Cells - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Germany Historic Review for Autologous Stem Cell and Non-Stem Cell Based Therapies by Type - Autologous Stem Cells and Autologous Non-Stem Cells Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 94: Germany 16-Year Perspective for Autologous Stem Cell and Non-Stem Cell Based Therapies by Type - Percentage Breakdown of Value Sales for Autologous Stem Cells and Autologous Non-Stem Cells for the Years 2014, 2025 & 2030
  • TABLE 95: Germany Recent Past, Current & Future Analysis for Autologous Stem Cell and Non-Stem Cell Based Therapies by End-user - Research Facilities End-User, Hospitals End-User and Ambulatory Surgery Centers End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Germany Historic Review for Autologous Stem Cell and Non-Stem Cell Based Therapies by End-user - Research Facilities End-User, Hospitals End-User and Ambulatory Surgery Centers End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 97: Germany 16-Year Perspective for Autologous Stem Cell and Non-Stem Cell Based Therapies by End-user - Percentage Breakdown of Value Sales for Research Facilities End-User, Hospitals End-User and Ambulatory Surgery Centers End-User for the Years 2014, 2025 & 2030
  • TABLE 98: Germany Recent Past, Current & Future Analysis for Autologous Stem Cell and Non-Stem Cell Based Therapies by Application - Cancer Application, Neurodegenerative Disorders Application, Cardiovascular Disease Application, Orthopedic Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Germany Historic Review for Autologous Stem Cell and Non-Stem Cell Based Therapies by Application - Cancer Application, Neurodegenerative Disorders Application, Cardiovascular Disease Application, Orthopedic Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 100: Germany 16-Year Perspective for Autologous Stem Cell and Non-Stem Cell Based Therapies by Application - Percentage Breakdown of Value Sales for Cancer Application, Neurodegenerative Disorders Application, Cardiovascular Disease Application, Orthopedic Diseases Application and Other Applications for the Years 2014, 2025 & 2030
• ITALY
  • TABLE 101: Italy Recent Past, Current & Future Analysis for Autologous Stem Cell and Non-Stem Cell Based Therapies by Type - Autologous Stem Cells and Autologous Non-Stem Cells - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Italy Historic Review for Autologous Stem Cell and Non-Stem Cell Based Therapies by Type - Autologous Stem Cells and Autologous Non-Stem Cells Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 103: Italy 16-Year Perspective for Autologous Stem Cell and Non-Stem Cell Based Therapies by Type - Percentage Breakdown of Value Sales for Autologous Stem Cells and Autologous Non-Stem Cells for the Years 2014, 2025 & 2030
  • TABLE 104: Italy Recent Past, Current & Future Analysis for Autologous Stem Cell and Non-Stem Cell Based Therapies by End-user - Research Facilities End-User, Hospitals End-User and Ambulatory Surgery Centers End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Italy Historic Review for Autologous Stem Cell and Non-Stem Cell Based Therapies by End-user - Research Facilities End-User, Hospitals End-User and Ambulatory Surgery Centers End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 106: Italy 16-Year Perspective for Autologous Stem Cell and Non-Stem Cell Based Therapies by End-user - Percentage Breakdown of Value Sales for Research Facilities End-User, Hospitals End-User and Ambulatory Surgery Centers End-User for the Years 2014, 2025 & 2030
  • TABLE 107: Italy Recent Past, Current & Future Analysis for Autologous Stem Cell and Non-Stem Cell Based Therapies by Application - Cancer Application, Neurodegenerative Disorders Application, Cardiovascular Disease Application, Orthopedic Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Italy Historic Review for Autologous Stem Cell and Non-Stem Cell Based Therapies by Application - Cancer Application, Neurodegenerative Disorders Application, Cardiovascular Disease Application, Orthopedic Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 109: Italy 16-Year Perspective for Autologous Stem Cell and Non-Stem Cell Based Therapies by Application - Percentage Breakdown of Value Sales for Cancer Application, Neurodegenerative Disorders Application, Cardiovascular Disease Application, Orthopedic Diseases Application and Other Applications for the Years 2014, 2025 & 2030
• UNITED KINGDOM
  • Autologous Stem Cell and Non-Stem Cell Based Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 110: UK Recent Past, Current & Future Analysis for Autologous Stem Cell and Non-Stem Cell Based Therapies by Type - Autologous Stem Cells and Autologous Non-Stem Cells - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: UK Historic Review for Autologous Stem Cell and Non-Stem Cell Based Therapies by Type - Autologous Stem Cells and Autologous Non-Stem Cells Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 112: UK 16-Year Perspective for Autologous Stem Cell and Non-Stem Cell Based Therapies by Type - Percentage Breakdown of Value Sales for Autologous Stem Cells and Autologous Non-Stem Cells for the Years 2014, 2025 & 2030
  • TABLE 113: UK Recent Past, Current & Future Analysis for Autologous Stem Cell and Non-Stem Cell Based Therapies by End-user - Research Facilities End-User, Hospitals End-User and Ambulatory Surgery Centers End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: UK Historic Review for Autologous Stem Cell and Non-Stem Cell Based Therapies by End-user - Research Facilities End-User, Hospitals End-User and Ambulatory Surgery Centers End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 115: UK 16-Year Perspective for Autologous Stem Cell and Non-Stem Cell Based Therapies by End-user - Percentage Breakdown of Value Sales for Research Facilities End-User, Hospitals End-User and Ambulatory Surgery Centers End-User for the Years 2014, 2025 & 2030
  • TABLE 116: UK Recent Past, Current & Future Analysis for Autologous Stem Cell and Non-Stem Cell Based Therapies by Application - Cancer Application, Neurodegenerative Disorders Application, Cardiovascular Disease Application, Orthopedic Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: UK Historic Review for Autologous Stem Cell and Non-Stem Cell Based Therapies by Application - Cancer Application, Neurodegenerative Disorders Application, Cardiovascular Disease Application, Orthopedic Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 118: UK 16-Year Perspective for Autologous Stem Cell and Non-Stem Cell Based Therapies by Application - Percentage Breakdown of Value Sales for Cancer Application, Neurodegenerative Disorders Application, Cardiovascular Disease Application, Orthopedic Diseases Application and Other Applications for the Years 2014, 2025 & 2030
• SPAIN
  • TABLE 119: Spain Recent Past, Current & Future Analysis for Autologous Stem Cell and Non-Stem Cell Based Therapies by Type - Autologous Stem Cells and Autologous Non-Stem Cells - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Spain Historic Review for Autologous Stem Cell and Non-Stem Cell Based Therapies by Type - Autologous Stem Cells and Autologous Non-Stem Cells Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 121: Spain 16-Year Perspective for Autologous Stem Cell and Non-Stem Cell Based Therapies by Type - Percentage Breakdown of Value Sales for Autologous Stem Cells and Autologous Non-Stem Cells for the Years 2014, 2025 & 2030
  • TABLE 122: Spain Recent Past, Current & Future Analysis for Autologous Stem Cell and Non-Stem Cell Based Therapies by End-user - Research Facilities End-User, Hospitals End-User and Ambulatory Surgery Centers End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Spain Historic Review for Autologous Stem Cell and Non-Stem Cell Based Therapies by End-user - Research Facilities End-User, Hospitals End-User and Ambulatory Surgery Centers End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 124: Spain 16-Year Perspective for Autologous Stem Cell and Non-Stem Cell Based Therapies by End-user - Percentage Breakdown of Value Sales for Research Facilities End-User, Hospitals End-User and Ambulatory Surgery Centers End-User for the Years 2014, 2025 & 2030
  • TABLE 125: Spain Recent Past, Current & Future Analysis for Autologous Stem Cell and Non-Stem Cell Based Therapies by Application - Cancer Application, Neurodegenerative Disorders Application, Cardiovascular Disease Application, Orthopedic Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Spain Historic Review for Autologous Stem Cell and Non-Stem Cell Based Therapies by Application - Cancer Application, Neurodegenerative Disorders Application, Cardiovascular Disease Application, Orthopedic Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 127: Spain 16-Year Perspective for Autologous Stem Cell and Non-Stem Cell Based Therapies by Application - Percentage Breakdown of Value Sales for Cancer Application, Neurodegenerative Disorders Application, Cardiovascular Disease Application, Orthopedic Diseases Application and Other Applications for the Years 2014, 2025 & 2030
• RUSSIA
  • TABLE 128: Russia Recent Past, Current & Future Analysis for Autologous Stem Cell and Non-Stem Cell Based Therapies by Type - Autologous Stem Cells and Autologous Non-Stem Cells - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Russia Historic Review for Autologous Stem Cell and Non-Stem Cell Based Therapies by Type - Autologous Stem Cells and Autologous Non-Stem Cells Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 130: Russia 16-Year Perspective for Autologous Stem Cell and Non-Stem Cell Based Therapies by Type - Percentage Breakdown of Value Sales for Autologous Stem Cells and Autologous Non-Stem Cells for the Years 2014, 2025 & 2030
  • TABLE 131: Russia Recent Past, Current & Future Analysis for Autologous Stem Cell and Non-Stem Cell Based Therapies by End-user - Research Facilities End-User, Hospitals End-User and Ambulatory Surgery Centers End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Russia Historic Review for Autologous Stem Cell and Non-Stem Cell Based Therapies by End-user - Research Facilities End-User, Hospitals End-User and Ambulatory Surgery Centers End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 133: Russia 16-Year Perspective for Autologous Stem Cell and Non-Stem Cell Based Therapies by End-user - Percentage Breakdown of Value Sales for Research Facilities End-User, Hospitals End-User and Ambulatory Surgery Centers End-User for the Years 2014, 2025 & 2030
  • TABLE 134: Russia Recent Past, Current & Future Analysis for Autologous Stem Cell and Non-Stem Cell Based Therapies by Application - Cancer Application, Neurodegenerative Disorders Application, Cardiovascular Disease Application, Orthopedic Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Russia Historic Review for Autologous Stem Cell and Non-Stem Cell Based Therapies by Application - Cancer Application, Neurodegenerative Disorders Application, Cardiovascular Disease Application, Orthopedic Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 136: Russia 16-Year Perspective for Autologous Stem Cell and Non-Stem Cell Based Therapies by Application - Percentage Breakdown of Value Sales for Cancer Application, Neurodegenerative Disorders Application, Cardiovascular Disease Application, Orthopedic Diseases Application and Other Applications for the Years 2014, 2025 & 2030
• REST OF EUROPE
  • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Autologous Stem Cell and Non-Stem Cell Based Therapies by Type - Autologous Stem Cells and Autologous Non-Stem Cells - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Rest of Europe Historic Review for Autologous Stem Cell and Non-Stem Cell Based Therapies by Type - Autologous Stem Cells and Autologous Non-Stem Cells Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 139: Rest of Europe 16-Year Perspective for Autologous Stem Cell and Non-Stem Cell Based Therapies by Type - Percentage Breakdown of Value Sales for Autologous Stem Cells and Autologous Non-Stem Cells for the Years 2014, 2025 & 2030
  • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Autologous Stem Cell and Non-Stem Cell Based Therapies by End-user - Research Facilities End-User, Hospitals End-User and Ambulatory Surgery Centers End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Rest of Europe Historic Review for Autologous Stem Cell and Non-Stem Cell Based Therapies by End-user - Research Facilities End-User, Hospitals End-User and Ambulatory Surgery Centers End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 142: Rest of Europe 16-Year Perspective for Autologous Stem Cell and Non-Stem Cell Based Therapies by End-user - Percentage Breakdown of Value Sales for Research Facilities End-User, Hospitals End-User and Ambulatory Surgery Centers End-User for the Years 2014, 2025 & 2030
  • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Autologous Stem Cell and Non-Stem Cell Based Therapies by Application - Cancer Application, Neurodegenerative Disorders Application, Cardiovascular Disease Application, Orthopedic Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Rest of Europe Historic Review for Autologous Stem Cell and Non-Stem Cell Based Therapies by Application - Cancer Application, Neurodegenerative Disorders Application, Cardiovascular Disease Application, Orthopedic Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 145: Rest of Europe 16-Year Perspective for Autologous Stem Cell and Non-Stem Cell Based Therapies by Application - Percentage Breakdown of Value Sales for Cancer Application, Neurodegenerative Disorders Application, Cardiovascular Disease Application, Orthopedic Diseases Application and Other Applications for the Years 2014, 2025 & 2030
• ASIA-PACIFIC
  • Autologous Stem Cell and Non-Stem Cell Based Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Autologous Stem Cell and Non-Stem Cell Based Therapies by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 147: Asia-Pacific Historic Review for Autologous Stem Cell and Non-Stem Cell Based Therapies by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 148: Asia-Pacific 16-Year Perspective for Autologous Stem Cell and Non-Stem Cell Based Therapies by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
  • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Autologous Stem Cell and Non-Stem Cell Based Therapies by Type - Autologous Stem Cells and Autologous Non-Stem Cells - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Asia-Pacific Historic Review for Autologous Stem Cell and Non-Stem Cell Based Therapies by Type - Autologous Stem Cells and Autologous Non-Stem Cells Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 151: Asia-Pacific 16-Year Perspective for Autologous Stem Cell and Non-Stem Cell Based Therapies by Type - Percentage Breakdown of Value Sales for Autologous Stem Cells and Autologous Non-Stem Cells for the Years 2014, 2025 & 2030
  • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Autologous Stem Cell and Non-Stem Cell Based Therapies by End-user - Research Facilities End-User, Hospitals End-User and Ambulatory Surgery Centers End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Asia-Pacific Historic Review for Autologous Stem Cell and Non-Stem Cell Based Therapies by End-user - Research Facilities End-User, Hospitals End-User and Ambulatory Surgery Centers End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 154: Asia-Pacific 16-Year Perspective for Autologous Stem Cell and Non-Stem Cell Based Therapies by End-user - Percentage Breakdown of Value Sales for Research Facilities End-User, Hospitals End-User and Ambulatory Surgery Centers End-User for the Years 2014, 2025 & 2030
  • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Autologous Stem Cell and Non-Stem Cell Based Therapies by Application - Cancer Application, Neurodegenerative Disorders Application, Cardiovascular Disease Application, Orthopedic Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Asia-Pacific Historic Review for Autologous Stem Cell and Non-Stem Cell Based Therapies by Application - Cancer Application, Neurodegenerative Disorders Application, Cardiovascular Disease Application, Orthopedic Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 157: Asia-Pacific 16-Year Perspective for Autologous Stem Cell and Non-Stem Cell Based Therapies by Application - Percentage Breakdown of Value Sales for Cancer Application, Neurodegenerative Disorders Application, Cardiovascular Disease Application, Orthopedic Diseases Application and Other Applications for the Years 2014, 2025 & 2030
• AUSTRALIA
  • Autologous Stem Cell and Non-Stem Cell Based Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 158: Australia Recent Past, Current & Future Analysis for Autologous Stem Cell and Non-Stem Cell Based Therapies by Type - Autologous Stem Cells and Autologous Non-Stem Cells - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Australia Historic Review for Autologous Stem Cell and Non-Stem Cell Based Therapies by Type - Autologous Stem Cells and Autologous Non-Stem Cells Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 160: Australia 16-Year Perspective for Autologous Stem Cell and Non-Stem Cell Based Therapies by Type - Percentage Breakdown of Value Sales for Autologous Stem Cells and Autologous Non-Stem Cells for the Years 2014, 2025 & 2030
  • TABLE 161: Australia Recent Past, Current & Future Analysis for Autologous Stem Cell and Non-Stem Cell Based Therapies by End-user - Research Facilities End-User, Hospitals End-User and Ambulatory Surgery Centers End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Australia Historic Review for Autologous Stem Cell and Non-Stem Cell Based Therapies by End-user - Research Facilities End-User, Hospitals End-User and Ambulatory Surgery Centers End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 163: Australia 16-Year Perspective for Autologous Stem Cell and Non-Stem Cell Based Therapies by End-user - Percentage Breakdown of Value Sales for Research Facilities End-User, Hospitals End-User and Ambulatory Surgery Centers End-User for the Years 2014, 2025 & 2030
  • TABLE 164: Australia Recent Past, Current & Future Analysis for Autologous Stem Cell and Non-Stem Cell Based Therapies by Application - Cancer Application, Neurodegenerative Disorders Application, Cardiovascular Disease Application, Orthopedic Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Australia Historic Review for Autologous Stem Cell and Non-Stem Cell Based Therapies by Application - Cancer Application, Neurodegenerative Disorders Application, Cardiovascular Disease Application, Orthopedic Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 166: Australia 16-Year Perspective for Autologous Stem Cell and Non-Stem Cell Based Therapies by Application - Percentage Breakdown of Value Sales for Cancer Application, Neurodegenerative Disorders Application, Cardiovascular Disease Application, Orthopedic Diseases Application and Other Applications for the Years 2014, 2025 & 2030
• INDIA
  • Autologous Stem Cell and Non-Stem Cell Based Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 167: India Recent Past, Current & Future Analysis for Autologous Stem Cell and Non-Stem Cell Based Therapies by Type - Autologous Stem Cells and Autologous Non-Stem Cells - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: India Historic Review for Autologous Stem Cell and Non-Stem Cell Based Therapies by Type - Autologous Stem Cells and Autologous Non-Stem Cells Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 169: India 16-Year Perspective for Autologous Stem Cell and Non-Stem Cell Based Therapies by Type - Percentage Breakdown of Value Sales for Autologous Stem Cells and Autologous Non-Stem Cells for the Years 2014, 2025 & 2030
  • TABLE 170: India Recent Past, Current & Future Analysis for Autologous Stem Cell and Non-Stem Cell Based Therapies by End-user - Research Facilities End-User, Hospitals End-User and Ambulatory Surgery Centers End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: India Historic Review for Autologous Stem Cell and Non-Stem Cell Based Therapies by End-user - Research Facilities End-User, Hospitals End-User and Ambulatory Surgery Centers End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 172: India 16-Year Perspective for Autologous Stem Cell and Non-Stem Cell Based Therapies by End-user - Percentage Breakdown of Value Sales for Research Facilities End-User, Hospitals End-User and Ambulatory Surgery Centers End-User for the Years 2014, 2025 & 2030
  • TABLE 173: India Recent Past, Current & Future Analysis for Autologous Stem Cell and Non-Stem Cell Based Therapies by Application - Cancer Application, Neurodegenerative Disorders Application, Cardiovascular Disease Application, Orthopedic Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: India Historic Review for Autologous Stem Cell and Non-Stem Cell Based Therapies by Application - Cancer Application, Neurodegenerative Disorders Application, Cardiovascular Disease Application, Orthopedic Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 175: India 16-Year Perspective for Autologous Stem Cell and Non-Stem Cell Based Therapies by Application - Percentage Breakdown of Value Sales for Cancer Application, Neurodegenerative Disorders Application, Cardiovascular Disease Application, Orthopedic Diseases Application and Other Applications for the Years 2014, 2025 & 2030
• SOUTH KOREA
  • TABLE 176: South Korea Recent Past, Current & Future Analysis for Autologous Stem Cell and Non-Stem Cell Based Therapies by Type - Autologous Stem Cells and Autologous Non-Stem Cells - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: South Korea Historic Review for Autologous Stem Cell and Non-Stem Cell Based Therapies by Type - Autologous Stem Cells and Autologous Non-Stem Cells Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 178: South Korea 16-Year Perspective for Autologous Stem Cell and Non-Stem Cell Based Therapies by Type - Percentage Breakdown of Value Sales for Autologous Stem Cells and Autologous Non-Stem Cells for the Years 2014, 2025 & 2030
  • TABLE 179: South Korea Recent Past, Current & Future Analysis for Autologous Stem Cell and Non-Stem Cell Based Therapies by End-user - Research Facilities End-User, Hospitals End-User and Ambulatory Surgery Centers End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: South Korea Historic Review for Autologous Stem Cell and Non-Stem Cell Based Therapies by End-user - Research Facilities End-User, Hospitals End-User and Ambulatory Surgery Centers End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 181: South Korea 16-Year Perspective for Autologous Stem Cell and Non-Stem Cell Based Therapies by End-user - Percentage Breakdown of Value Sales for Research Facilities End-User, Hospitals End-User and Ambulatory Surgery Centers End-User for the Years 2014, 2025 & 2030
  • TABLE 182: South Korea Recent Past, Current & Future Analysis for Autologous Stem Cell and Non-Stem Cell Based Therapies by Application - Cancer Application, Neurodegenerative Disorders Application, Cardiovascular Disease Application, Orthopedic Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: South Korea Historic Review for Autologous Stem Cell and Non-Stem Cell Based Therapies by Application - Cancer Application, Neurodegenerative Disorders Application, Cardiovascular Disease Application, Orthopedic Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 184: South Korea 16-Year Perspective for Autologous Stem Cell and Non-Stem Cell Based Therapies by Application - Percentage Breakdown of Value Sales for Cancer Application, Neurodegenerative Disorders Application, Cardiovascular Disease Application, Orthopedic Diseases Application and Other Applications for the Years 2014, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Autologous Stem Cell and Non-Stem Cell Based Therapies by Type - Autologous Stem Cells and Autologous Non-Stem Cells - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Rest of Asia-Pacific Historic Review for Autologous Stem Cell and Non-Stem Cell Based Therapies by Type - Autologous Stem Cells and Autologous Non-Stem Cells Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 187: Rest of Asia-Pacific 16-Year Perspective for Autologous Stem Cell and Non-Stem Cell Based Therapies by Type - Percentage Breakdown of Value Sales for Autologous Stem Cells and Autologous Non-Stem Cells for the Years 2014, 2025 & 2030
  • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Autologous Stem Cell and Non-Stem Cell Based Therapies by End-user - Research Facilities End-User, Hospitals End-User and Ambulatory Surgery Centers End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Rest of Asia-Pacific Historic Review for Autologous Stem Cell and Non-Stem Cell Based Therapies by End-user - Research Facilities End-User, Hospitals End-User and Ambulatory Surgery Centers End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 190: Rest of Asia-Pacific 16-Year Perspective for Autologous Stem Cell and Non-Stem Cell Based Therapies by End-user - Percentage Breakdown of Value Sales for Research Facilities End-User, Hospitals End-User and Ambulatory Surgery Centers End-User for the Years 2014, 2025 & 2030
  • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Autologous Stem Cell and Non-Stem Cell Based Therapies by Application - Cancer Application, Neurodegenerative Disorders Application, Cardiovascular Disease Application, Orthopedic Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Rest of Asia-Pacific Historic Review for Autologous Stem Cell and Non-Stem Cell Based Therapies by Application - Cancer Application, Neurodegenerative Disorders Application, Cardiovascular Disease Application, Orthopedic Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 193: Rest of Asia-Pacific 16-Year Perspective for Autologous Stem Cell and Non-Stem Cell Based Therapies by Application - Percentage Breakdown of Value Sales for Cancer Application, Neurodegenerative Disorders Application, Cardiovascular Disease Application, Orthopedic Diseases Application and Other Applications for the Years 2014, 2025 & 2030
• LATIN AMERICA
  • Autologous Stem Cell and Non-Stem Cell Based Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 194: Latin America Recent Past, Current & Future Analysis for Autologous Stem Cell and Non-Stem Cell Based Therapies by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 195: Latin America Historic Review for Autologous Stem Cell and Non-Stem Cell Based Therapies by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 196: Latin America 16-Year Perspective for Autologous Stem Cell and Non-Stem Cell Based Therapies by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
  • TABLE 197: Latin America Recent Past, Current & Future Analysis for Autologous Stem Cell and Non-Stem Cell Based Therapies by Type - Autologous Stem Cells and Autologous Non-Stem Cells - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Latin America Historic Review for Autologous Stem Cell and Non-Stem Cell Based Therapies by Type - Autologous Stem Cells and Autologous Non-Stem Cells Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 199: Latin America 16-Year Perspective for Autologous Stem Cell and Non-Stem Cell Based Therapies by Type - Percentage Breakdown of Value Sales for Autologous Stem Cells and Autologous Non-Stem Cells for the Years 2014, 2025 & 2030
  • TABLE 200: Latin America Recent Past, Current & Future Analysis for Autologous Stem Cell and Non-Stem Cell Based Therapies by End-user - Research Facilities End-User, Hospitals End-User and Ambulatory Surgery Centers End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Latin America Historic Review for Autologous Stem Cell and Non-Stem Cell Based Therapies by End-user - Research Facilities End-User, Hospitals End-User and Ambulatory Surgery Centers End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 202: Latin America 16-Year Perspective for Autologous Stem Cell and Non-Stem Cell Based Therapies by End-user - Percentage Breakdown of Value Sales for Research Facilities End-User, Hospitals End-User and Ambulatory Surgery Centers End-User for the Years 2014, 2025 & 2030
  • TABLE 203: Latin America Recent Past, Current & Future Analysis for Autologous Stem Cell and Non-Stem Cell Based Therapies by Application - Cancer Application, Neurodegenerative Disorders Application, Cardiovascular Disease Application, Orthopedic Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Latin America Historic Review for Autologous Stem Cell and Non-Stem Cell Based Therapies by Application - Cancer Application, Neurodegenerative Disorders Application, Cardiovascular Disease Application, Orthopedic Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 205: Latin America 16-Year Perspective for Autologous Stem Cell and Non-Stem Cell Based Therapies by Application - Percentage Breakdown of Value Sales for Cancer Application, Neurodegenerative Disorders Application, Cardiovascular Disease Application, Orthopedic Diseases Application and Other Applications for the Years 2014, 2025 & 2030
• ARGENTINA
  • TABLE 206: Argentina Recent Past, Current & Future Analysis for Autologous Stem Cell and Non-Stem Cell Based Therapies by Type - Autologous Stem Cells and Autologous Non-Stem Cells - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Argentina Historic Review for Autologous Stem Cell and Non-Stem Cell Based Therapies by Type - Autologous Stem Cells and Autologous Non-Stem Cells Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 208: Argentina 16-Year Perspective for Autologous Stem Cell and Non-Stem Cell Based Therapies by Type - Percentage Breakdown of Value Sales for Autologous Stem Cells and Autologous Non-Stem Cells for the Years 2014, 2025 & 2030
  • TABLE 209: Argentina Recent Past, Current & Future Analysis for Autologous Stem Cell and Non-Stem Cell Based Therapies by End-user - Research Facilities End-User, Hospitals End-User and Ambulatory Surgery Centers End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Argentina Historic Review for Autologous Stem Cell and Non-Stem Cell Based Therapies by End-user - Research Facilities End-User, Hospitals End-User and Ambulatory Surgery Centers End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 211: Argentina 16-Year Perspective for Autologous Stem Cell and Non-Stem Cell Based Therapies by End-user - Percentage Breakdown of Value Sales for Research Facilities End-User, Hospitals End-User and Ambulatory Surgery Centers End-User for the Years 2014, 2025 & 2030
  • TABLE 212: Argentina Recent Past, Current & Future Analysis for Autologous Stem Cell and Non-Stem Cell Based Therapies by Application - Cancer Application, Neurodegenerative Disorders Application, Cardiovascular Disease Application, Orthopedic Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Argentina Historic Review for Autologous Stem Cell and Non-Stem Cell Based Therapies by Application - Cancer Application, Neurodegenerative Disorders Application, Cardiovascular Disease Application, Orthopedic Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 214: Argentina 16-Year Perspective for Autologous Stem Cell and Non-Stem Cell Based Therapies by Application - Percentage Breakdown of Value Sales for Cancer Application, Neurodegenerative Disorders Application, Cardiovascular Disease Application, Orthopedic Diseases Application and Other Applications for the Years 2014, 2025 & 2030
• BRAZIL
  • TABLE 215: Brazil Recent Past, Current & Future Analysis for Autologous Stem Cell and Non-Stem Cell Based Therapies by Type - Autologous Stem Cells and Autologous Non-Stem Cells - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Brazil Historic Review for Autologous Stem Cell and Non-Stem Cell Based Therapies by Type - Autologous Stem Cells and Autologous Non-Stem Cells Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 217: Brazil 16-Year Perspective for Autologous Stem Cell and Non-Stem Cell Based Therapies by Type - Percentage Breakdown of Value Sales for Autologous Stem Cells and Autologous Non-Stem Cells for the Years 2014, 2025 & 2030
  • TABLE 218: Brazil Recent Past, Current & Future Analysis for Autologous Stem Cell and Non-Stem Cell Based Therapies by End-user - Research Facilities End-User, Hospitals End-User and Ambulatory Surgery Centers End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Brazil Historic Review for Autologous Stem Cell and Non-Stem Cell Based Therapies by End-user - Research Facilities End-User, Hospitals End-User and Ambulatory Surgery Centers End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 220: Brazil 16-Year Perspective for Autologous Stem Cell and Non-Stem Cell Based Therapies by End-user - Percentage Breakdown of Value Sales for Research Facilities End-User, Hospitals End-User and Ambulatory Surgery Centers End-User for the Years 2014, 2025 & 2030
  • TABLE 221: Brazil Recent Past, Current & Future Analysis for Autologous Stem Cell and Non-Stem Cell Based Therapies by Application - Cancer Application, Neurodegenerative Disorders Application, Cardiovascular Disease Application, Orthopedic Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Brazil Historic Review for Autologous Stem Cell and Non-Stem Cell Based Therapies by Application - Cancer Application, Neurodegenerative Disorders Application, Cardiovascular Disease Application, Orthopedic Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 223: Brazil 16-Year Perspective for Autologous Stem Cell and Non-Stem Cell Based Therapies by Application - Percentage Breakdown of Value Sales for Cancer Application, Neurodegenerative Disorders Application, Cardiovascular Disease Application, Orthopedic Diseases Application and Other Applications for the Years 2014, 2025 & 2030
• MEXICO
  • TABLE 224: Mexico Recent Past, Current & Future Analysis for Autologous Stem Cell and Non-Stem Cell Based Therapies by Type - Autologous Stem Cells and Autologous Non-Stem Cells - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Mexico Historic Review for Autologous Stem Cell and Non-Stem Cell Based Therapies by Type - Autologous Stem Cells and Autologous Non-Stem Cells Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 226: Mexico 16-Year Perspective for Autologous Stem Cell and Non-Stem Cell Based Therapies by Type - Percentage Breakdown of Value Sales for Autologous Stem Cells and Autologous Non-Stem Cells for the Years 2014, 2025 & 2030
  • TABLE 227: Mexico Recent Past, Current & Future Analysis for Autologous Stem Cell and Non-Stem Cell Based Therapies by End-user - Research Facilities End-User, Hospitals End-User and Ambulatory Surgery Centers End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Mexico Historic Review for Autologous Stem Cell and Non-Stem Cell Based Therapies by End-user - Research Facilities End-User, Hospitals End-User and Ambulatory Surgery Centers End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 229: Mexico 16-Year Perspective for Autologous Stem Cell and Non-Stem Cell Based Therapies by End-user - Percentage Breakdown of Value Sales for Research Facilities End-User, Hospitals End-User and Ambulatory Surgery Centers End-User for the Years 2014, 2025 & 2030
  • TABLE 230: Mexico Recent Past, Current & Future Analysis for Autologous Stem Cell and Non-Stem Cell Based Therapies by Application - Cancer Application, Neurodegenerative Disorders Application, Cardiovascular Disease Application, Orthopedic Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Mexico Historic Review for Autologous Stem Cell and Non-Stem Cell Based Therapies by Application - Cancer Application, Neurodegenerative Disorders Application, Cardiovascular Disease Application, Orthopedic Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 232: Mexico 16-Year Perspective for Autologous Stem Cell and Non-Stem Cell Based Therapies by Application - Percentage Breakdown of Value Sales for Cancer Application, Neurodegenerative Disorders Application, Cardiovascular Disease Application, Orthopedic Diseases Application and Other Applications for the Years 2014, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Autologous Stem Cell and Non-Stem Cell Based Therapies by Type - Autologous Stem Cells and Autologous Non-Stem Cells - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Rest of Latin America Historic Review for Autologous Stem Cell and Non-Stem Cell Based Therapies by Type - Autologous Stem Cells and Autologous Non-Stem Cells Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 235: Rest of Latin America 16-Year Perspective for Autologous Stem Cell and Non-Stem Cell Based Therapies by Type - Percentage Breakdown of Value Sales for Autologous Stem Cells and Autologous Non-Stem Cells for the Years 2014, 2025 & 2030
  • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Autologous Stem Cell and Non-Stem Cell Based Therapies by End-user - Research Facilities End-User, Hospitals End-User and Ambulatory Surgery Centers End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Rest of Latin America Historic Review for Autologous Stem Cell and Non-Stem Cell Based Therapies by End-user - Research Facilities End-User, Hospitals End-User and Ambulatory Surgery Centers End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 238: Rest of Latin America 16-Year Perspective for Autologous Stem Cell and Non-Stem Cell Based Therapies by End-user - Percentage Breakdown of Value Sales for Research Facilities End-User, Hospitals End-User and Ambulatory Surgery Centers End-User for the Years 2014, 2025 & 2030
  • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Autologous Stem Cell and Non-Stem Cell Based Therapies by Application - Cancer Application, Neurodegenerative Disorders Application, Cardiovascular Disease Application, Orthopedic Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Rest of Latin America Historic Review for Autologous Stem Cell and Non-Stem Cell Based Therapies by Application - Cancer Application, Neurodegenerative Disorders Application, Cardiovascular Disease Application, Orthopedic Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 241: Rest of Latin America 16-Year Perspective for Autologous Stem Cell and Non-Stem Cell Based Therapies by Application - Percentage Breakdown of Value Sales for Cancer Application, Neurodegenerative Disorders Application, Cardiovascular Disease Application, Orthopedic Diseases Application and Other Applications for the Years 2014, 2025 & 2030
• MIDDLE EAST
  • Autologous Stem Cell and Non-Stem Cell Based Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 242: Middle East Recent Past, Current & Future Analysis for Autologous Stem Cell and Non-Stem Cell Based Therapies by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 243: Middle East Historic Review for Autologous Stem Cell and Non-Stem Cell Based Therapies by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 244: Middle East 16-Year Perspective for Autologous Stem Cell and Non-Stem Cell Based Therapies by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
  • TABLE 245: Middle East Recent Past, Current & Future Analysis for Autologous Stem Cell and Non-Stem Cell Based Therapies by Type - Autologous Stem Cells and Autologous Non-Stem Cells - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Middle East Historic Review for Autologous Stem Cell and Non-Stem Cell Based Therapies by Type - Autologous Stem Cells and Autologous Non-Stem Cells Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 247: Middle East 16-Year Perspective for Autologous Stem Cell and Non-Stem Cell Based Therapies by Type - Percentage Breakdown of Value Sales for Autologous Stem Cells and Autologous Non-Stem Cells for the Years 2014, 2025 & 2030
  • TABLE 248: Middle East Recent Past, Current & Future Analysis for Autologous Stem Cell and Non-Stem Cell Based Therapies by End-user - Research Facilities End-User, Hospitals End-User and Ambulatory Surgery Centers End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Middle East Historic Review for Autologous Stem Cell and Non-Stem Cell Based Therapies by End-user - Research Facilities End-User, Hospitals End-User and Ambulatory Surgery Centers End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 250: Middle East 16-Year Perspective for Autologous Stem Cell and Non-Stem Cell Based Therapies by End-user - Percentage Breakdown of Value Sales for Research Facilities End-User, Hospitals End-User and Ambulatory Surgery Centers End-User for the Years 2014, 2025 & 2030
  • TABLE 251: Middle East Recent Past, Current & Future Analysis for Autologous Stem Cell and Non-Stem Cell Based Therapies by Application - Cancer Application, Neurodegenerative Disorders Application, Cardiovascular Disease Application, Orthopedic Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Middle East Historic Review for Autologous Stem Cell and Non-Stem Cell Based Therapies by Application - Cancer Application, Neurodegenerative Disorders Application, Cardiovascular Disease Application, Orthopedic Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 253: Middle East 16-Year Perspective for Autologous Stem Cell and Non-Stem Cell Based Therapies by Application - Percentage Breakdown of Value Sales for Cancer Application, Neurodegenerative Disorders Application, Cardiovascular Disease Application, Orthopedic Diseases Application and Other Applications for the Years 2014, 2025 & 2030
• IRAN
  • TABLE 254: Iran Recent Past, Current & Future Analysis for Autologous Stem Cell and Non-Stem Cell Based Therapies by Type - Autologous Stem Cells and Autologous Non-Stem Cells - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Iran Historic Review for Autologous Stem Cell and Non-Stem Cell Based Therapies by Type - Autologous Stem Cells and Autologous Non-Stem Cells Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 256: Iran 16-Year Perspective for Autologous Stem Cell and Non-Stem Cell Based Therapies by Type - Percentage Breakdown of Value Sales for Autologous Stem Cells and Autologous Non-Stem Cells for the Years 2014, 2025 & 2030
  • TABLE 257: Iran Recent Past, Current & Future Analysis for Autologous Stem Cell and Non-Stem Cell Based Therapies by End-user - Research Facilities End-User, Hospitals End-User and Ambulatory Surgery Centers End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Iran Historic Review for Autologous Stem Cell and Non-Stem Cell Based Therapies by End-user - Research Facilities End-User, Hospitals End-User and Ambulatory Surgery Centers End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 259: Iran 16-Year Perspective for Autologous Stem Cell and Non-Stem Cell Based Therapies by End-user - Percentage Breakdown of Value Sales for Research Facilities End-User, Hospitals End-User and Ambulatory Surgery Centers End-User for the Years 2014, 2025 & 2030
  • TABLE 260: Iran Recent Past, Current & Future Analysis for Autologous Stem Cell and Non-Stem Cell Based Therapies by Application - Cancer Application, Neurodegenerative Disorders Application, Cardiovascular Disease Application, Orthopedic Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Iran Historic Review for Autologous Stem Cell and Non-Stem Cell Based Therapies by Application - Cancer Application, Neurodegenerative Disorders Application, Cardiovascular Disease Application, Orthopedic Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 262: Iran 16-Year Perspective for Autologous Stem Cell and Non-Stem Cell Based Therapies by Application - Percentage Breakdown of Value Sales for Cancer Application, Neurodegenerative Disorders Application, Cardiovascular Disease Application, Orthopedic Diseases Application and Other Applications for the Years 2014, 2025 & 2030
• ISRAEL
  • TABLE 263: Israel Recent Past, Current & Future Analysis for Autologous Stem Cell and Non-Stem Cell Based Therapies by Type - Autologous Stem Cells and Autologous Non-Stem Cells - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Israel Historic Review for Autologous Stem Cell and Non-Stem Cell Based Therapies by Type - Autologous Stem Cells and Autologous Non-Stem Cells Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 265: Israel 16-Year Perspective for Autologous Stem Cell and Non-Stem Cell Based Therapies by Type - Percentage Breakdown of Value Sales for Autologous Stem Cells and Autologous Non-Stem Cells for the Years 2014, 2025 & 2030
  • TABLE 266: Israel Recent Past, Current & Future Analysis for Autologous Stem Cell and Non-Stem Cell Based Therapies by End-user - Research Facilities End-User, Hospitals End-User and Ambulatory Surgery Centers End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Israel Historic Review for Autologous Stem Cell and Non-Stem Cell Based Therapies by End-user - Research Facilities End-User, Hospitals End-User and Ambulatory Surgery Centers End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 268: Israel 16-Year Perspective for Autologous Stem Cell and Non-Stem Cell Based Therapies by End-user - Percentage Breakdown of Value Sales for Research Facilities End-User, Hospitals End-User and Ambulatory Surgery Centers End-User for the Years 2014, 2025 & 2030
  • TABLE 269: Israel Recent Past, Current & Future Analysis for Autologous Stem Cell and Non-Stem Cell Based Therapies by Application - Cancer Application, Neurodegenerative Disorders Application, Cardiovascular Disease Application, Orthopedic Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Israel Historic Review for Autologous Stem Cell and Non-Stem Cell Based Therapies by Application - Cancer Application, Neurodegenerative Disorders Application, Cardiovascular Disease Application, Orthopedic Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 271: Israel 16-Year Perspective for Autologous Stem Cell and Non-Stem Cell Based Therapies by Application - Percentage Breakdown of Value Sales for Cancer Application, Neurodegenerative Disorders Application, Cardiovascular Disease Application, Orthopedic Diseases Application and Other Applications for the Years 2014, 2025 & 2030
• SAUDI ARABIA
  • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Autologous Stem Cell and Non-Stem Cell Based Therapies by Type - Autologous Stem Cells and Autologous Non-Stem Cells - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Saudi Arabia Historic Review for Autologous Stem Cell and Non-Stem Cell Based Therapies by Type - Autologous Stem Cells and Autologous Non-Stem Cells Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 274: Saudi Arabia 16-Year Perspective for Autologous Stem Cell and Non-Stem Cell Based Therapies by Type - Percentage Breakdown of Value Sales for Autologous Stem Cells and Autologous Non-Stem Cells for the Years 2014, 2025 & 2030
  • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Autologous Stem Cell and Non-Stem Cell Based Therapies by End-user - Research Facilities End-User, Hospitals End-User and Ambulatory Surgery Centers End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Saudi Arabia Historic Review for Autologous Stem Cell and Non-Stem Cell Based Therapies by End-user - Research Facilities End-User, Hospitals End-User and Ambulatory Surgery Centers End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 277: Saudi Arabia 16-Year Perspective for Autologous Stem Cell and Non-Stem Cell Based Therapies by End-user - Percentage Breakdown of Value Sales for Research Facilities End-User, Hospitals End-User and Ambulatory Surgery Centers End-User for the Years 2014, 2025 & 2030
  • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Autologous Stem Cell and Non-Stem Cell Based Therapies by Application - Cancer Application, Neurodegenerative Disorders Application, Cardiovascular Disease Application, Orthopedic Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Saudi Arabia Historic Review for Autologous Stem Cell and Non-Stem Cell Based Therapies by Application - Cancer Application, Neurodegenerative Disorders Application, Cardiovascular Disease Application, Orthopedic Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 280: Saudi Arabia 16-Year Perspective for Autologous Stem Cell and Non-Stem Cell Based Therapies by Application - Percentage Breakdown of Value Sales for Cancer Application, Neurodegenerative Disorders Application, Cardiovascular Disease Application, Orthopedic Diseases Application and Other Applications for the Years 2014, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 281: UAE Recent Past, Current & Future Analysis for Autologous Stem Cell and Non-Stem Cell Based Therapies by Type - Autologous Stem Cells and Autologous Non-Stem Cells - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: UAE Historic Review for Autologous Stem Cell and Non-Stem Cell Based Therapies by Type - Autologous Stem Cells and Autologous Non-Stem Cells Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 283: UAE 16-Year Perspective for Autologous Stem Cell and Non-Stem Cell Based Therapies by Type - Percentage Breakdown of Value Sales for Autologous Stem Cells and Autologous Non-Stem Cells for the Years 2014, 2025 & 2030
  • TABLE 284: UAE Recent Past, Current & Future Analysis for Autologous Stem Cell and Non-Stem Cell Based Therapies by End-user - Research Facilities End-User, Hospitals End-User and Ambulatory Surgery Centers End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: UAE Historic Review for Autologous Stem Cell and Non-Stem Cell Based Therapies by End-user - Research Facilities End-User, Hospitals End-User and Ambulatory Surgery Centers End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 286: UAE 16-Year Perspective for Autologous Stem Cell and Non-Stem Cell Based Therapies by End-user - Percentage Breakdown of Value Sales for Research Facilities End-User, Hospitals End-User and Ambulatory Surgery Centers End-User for the Years 2014, 2025 & 2030
  • TABLE 287: UAE Recent Past, Current & Future Analysis for Autologous Stem Cell and Non-Stem Cell Based Therapies by Application - Cancer Application, Neurodegenerative Disorders Application, Cardiovascular Disease Application, Orthopedic Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: UAE Historic Review for Autologous Stem Cell and Non-Stem Cell Based Therapies by Application - Cancer Application, Neurodegenerative Disorders Application, Cardiovascular Disease Application, Orthopedic Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 289: UAE 16-Year Perspective for Autologous Stem Cell and Non-Stem Cell Based Therapies by Application - Percentage Breakdown of Value Sales for Cancer Application, Neurodegenerative Disorders Application, Cardiovascular Disease Application, Orthopedic Diseases Application and Other Applications for the Years 2014, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Autologous Stem Cell and Non-Stem Cell Based Therapies by Type - Autologous Stem Cells and Autologous Non-Stem Cells - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Rest of Middle East Historic Review for Autologous Stem Cell and Non-Stem Cell Based Therapies by Type - Autologous Stem Cells and Autologous Non-Stem Cells Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 292: Rest of Middle East 16-Year Perspective for Autologous Stem Cell and Non-Stem Cell Based Therapies by Type - Percentage Breakdown of Value Sales for Autologous Stem Cells and Autologous Non-Stem Cells for the Years 2014, 2025 & 2030
  • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Autologous Stem Cell and Non-Stem Cell Based Therapies by End-user - Research Facilities End-User, Hospitals End-User and Ambulatory Surgery Centers End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Rest of Middle East Historic Review for Autologous Stem Cell and Non-Stem Cell Based Therapies by End-user - Research Facilities End-User, Hospitals End-User and Ambulatory Surgery Centers End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 295: Rest of Middle East 16-Year Perspective for Autologous Stem Cell and Non-Stem Cell Based Therapies by End-user - Percentage Breakdown of Value Sales for Research Facilities End-User, Hospitals End-User and Ambulatory Surgery Centers End-User for the Years 2014, 2025 & 2030
  • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Autologous Stem Cell and Non-Stem Cell Based Therapies by Application - Cancer Application, Neurodegenerative Disorders Application, Cardiovascular Disease Application, Orthopedic Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Rest of Middle East Historic Review for Autologous Stem Cell and Non-Stem Cell Based Therapies by Application - Cancer Application, Neurodegenerative Disorders Application, Cardiovascular Disease Application, Orthopedic Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 298: Rest of Middle East 16-Year Perspective for Autologous Stem Cell and Non-Stem Cell Based Therapies by Application - Percentage Breakdown of Value Sales for Cancer Application, Neurodegenerative Disorders Application, Cardiovascular Disease Application, Orthopedic Diseases Application and Other Applications for the Years 2014, 2025 & 2030
• AFRICA
  • Autologous Stem Cell and Non-Stem Cell Based Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 299: Africa Recent Past, Current & Future Analysis for Autologous Stem Cell and Non-Stem Cell Based Therapies by Type - Autologous Stem Cells and Autologous Non-Stem Cells - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Africa Historic Review for Autologous Stem Cell and Non-Stem Cell Based Therapies by Type - Autologous Stem Cells and Autologous Non-Stem Cells Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 301: Africa 16-Year Perspective for Autologous Stem Cell and Non-Stem Cell Based Therapies by Type - Percentage Breakdown of Value Sales for Autologous Stem Cells and Autologous Non-Stem Cells for the Years 2014, 2025 & 2030
  • TABLE 302: Africa Recent Past, Current & Future Analysis for Autologous Stem Cell and Non-Stem Cell Based Therapies by End-user - Research Facilities End-User, Hospitals End-User and Ambulatory Surgery Centers End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Africa Historic Review for Autologous Stem Cell and Non-Stem Cell Based Therapies by End-user - Research Facilities End-User, Hospitals End-User and Ambulatory Surgery Centers End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 304: Africa 16-Year Perspective for Autologous Stem Cell and Non-Stem Cell Based Therapies by End-user - Percentage Breakdown of Value Sales for Research Facilities End-User, Hospitals End-User and Ambulatory Surgery Centers End-User for the Years 2014, 2025 & 2030
  • TABLE 305: Africa Recent Past, Current & Future Analysis for Autologous Stem Cell and Non-Stem Cell Based Therapies by Application - Cancer Application, Neurodegenerative Disorders Application, Cardiovascular Disease Application, Orthopedic Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Africa Historic Review for Autologous Stem Cell and Non-Stem Cell Based Therapies by Application - Cancer Application, Neurodegenerative Disorders Application, Cardiovascular Disease Application, Orthopedic Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 307: Africa 16-Year Perspective for Autologous Stem Cell and Non-Stem Cell Based Therapies by Application - Percentage Breakdown of Value Sales for Cancer Application, Neurodegenerative Disorders Application, Cardiovascular Disease Application, Orthopedic Diseases Application and Other Applications for the Years 2014, 2025 & 2030

IV. COMPETITION